Exposure-response analyses of sacituzumab govitecan (SG) efficacy and safety in patients (pts) with metastatic triple-negative breast cancer (mTNBC).
JOURNAL OF CLINICAL ONCOLOGY(2022)
关键词
breast cancer,sacituzumab govitecan,metastatic,exposure-response,triple-negative
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要